Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on Monday, April 17 at 9:30 a.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:Courtney TurianoStern Investor Relations, Inc.[email protected] (212) 698-8687

Media Contact:Gabriella GreigReal Chemistry[email protected](203) 249-2688

You May Also Be Interested In

• Shentel and Glo Fiber Honored with 2026 CFX Top Ops Award for Community Relations
• Dimensional Fund Advisors Ltd. : Form 8.3 - SENIOR PLC - Ordinary Shares
• Dimensional Fund Advisors Ltd. : Form 8.3 - VESUVIUS PLC - Ordinary Shares